Gene therapy shows promise in treating heart arrhythmia: Study

A pharmaceutical gene therapy has shown promise in treating calmodulinopathy, a rare and hard-to-treat heart arrhythmia, according to a study published Aug. 19 in Circulation

Advertisement

Three genes — CALM1, CALM2 and CALM3 — are associated with heart function. A damaging variant in CALM1 causes calmodulinopathy. 

Researchers from Boston Children’s Hospital said they have found a “safe and effective” pharmaceutical therapy for treating the disease, according to a Sept. 18 news release from the hospital. The antisense oligonucleotide pharmaceutical treatment targets the CALM1 gene variant at the RNA level without affecting the other CALM genes. 

Advertisement

Next Up in Cardiology

Advertisement

Leave a Reply

Your email address will not be published. Required fields are marked *